More specifically, these results support the hypothesis that ADAR1-mediated MAVS editing can lead to increased MAVS protein levels and to increased, non-canonical downstream signaling, especially through NF-κB, a key oncogenic signaling pathway in DLBCL pathogenesis. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.